The respiratory syncytial virus (RSV) prophylaxis market across the eight major markets (8MM) - comprising the US, the five major European markets (France, Germany, Italy, Spain, and the UK), Japan, ...

For comparison, Pfizer reported yesterday that Abrysvo made full-year sales of $890 million, which - while respectable - were well below its competitor. However, it brought in $515 million in the ...

After hours: December 9 at 6:06:40 PM EST ...

mResvia’s top-line score comes in slightly lower than Arexvy and slightly above Abrysvo, they note – notwithstanding differences in study design – and will be weighed up against the ...

The FDA has approved three vaccines to prevent RSV in adults who are 60 and older: Moderna’s mRESVIA, approved in June 2024, and GSK’s Arexvy and Pfizer’s Abrysvo, both approved in May 2023. The ...

(NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF ...

Nirsevimab is recommended for all infants younger than 8 months whose mothers did not receive the maternal RSV vaccine (Abrysvo; Pfizer) during pregnancy. It should be administered shortly before ...

Employers Shift to Equity-Focused Strategies as Health Costs Outpace Wages ...